Fletcher Biosciences is developing a new generation of precision biologics designed to selectively target disease-driving immune cells. Current immunotherapies often lack the ability to precisely target the immune cells driving disease, forcing reliance on broad immune suppression or modulation that can disrupt healthy immune function. Fletcher is building a platform to design biologic therapies that precisely engage defined immune cell populations, enabling targeted approaches to correcting immune dysfunction across autoimmune disease, oncology, and infectious disease.
| Website | https://www.fletcherbio.com/ |
| Employees | 5 (5 on RocketReach) |
| Founded | 2023 |
| Address | 700 Main St, Cambridge, Massachusetts 02139, US |
| Industry | Biotechnology Research |
| Keywords | Protein Therapeutics, T Cell Therapy, Biotechnology, Pharmaceutical Research, Immunotherapy, Drug Development, Biologics, Cell Therapy, Protein Engineering, Therapeutic Proteins, Biopharmaceutical, Clinical Trials, Molecular Biology, Life Sciences, Bioprocessing, Pharmaceutical, Research And Development, Genetic Engineering, Medicine, Healthcare |
Looking for a particular Fletcher Biosciences employee's phone or email?
Patrick Holec is the CEO, co-founder of Fletcher Biosciences.
5 people are employed at Fletcher Biosciences.
Fletcher Biosciences is based in Cambridge, Massachusetts.